Together, this result revealed the role of TP53 mutations in promoting tumor cell proliferation, through CDK4-mediated signaling pathway in younger patients, and suggested promising therapeutical options of younger TP53-mutant patients by CDK4 inhibitors (Fig. 2T). This evidence concerns the gene TP53 and neoplasm.